Assessment of the effects of prepartum anti-inflammatory therapies on type 1/type 2 immunity ratio using a rapid blood test

Autor: J. Spring, Q. Huo, E. Jimenez, M. Martinez, P. Zarei, J. Lection, E. Hovingh, J. Lawhead, R.H. Sorto Cruz, A.A. Barragan

Publikováno v: JDS Communications, Vol 5, Iss 2, Pp 144-149 (2024)

Abstract:: The objective of this study was to assess (1) the effects of prepartum administration of anti-inflammatory therapies on type 1/type 2 immunity ratio using a rapid blood test (D2Dx immunity test; Nano Discovery Inc.), and (2) correlations b

Externí odkaz: https://doaj.org/article/8389aafca4294267965ad677b30d8e4a

A bounded actor–critic reinforcement learning algorithm applied to airline revenue management

Autor: Abhijit Gosavi, Ryan J. Lawhead

Publikováno v: Engineering Applications of Artificial Intelligence. 82:252-262

Reinforcement Learning (RL) is an artificial intelligence technique used to solve Markov and semi-Markov decision processes. Actor critics form a major class of RL algorithms that suffer from a critical deficiency, which is that the values of the so-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::80d1765ac8c44ddb022c42924a021596
https://doi.org/10.1016/j.engappai.2019.04.008

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5):a placebo-controlled, randomised, phase 3a trial

Autor: Robert Silver, G Bedel, M Yanovskaya, Simon Heller, T Hart, A Golovach, G Cornett, A Luts, A Chang, L Lewy-Alterbaum, H Nguyen, S Hasan, Amir Tirosh, W Biggs, R Pratley, K Blaze, Ole Holm Hels, A Peskov, P Houser, E Klein, Peter Rossing, H Knoble, T Milovanova, P O'Donnell, S Folkerth, H A Frandsen, S Chandran, A Krzeminski, Richard E. Pratley, J Reed, S Sulosaari, Torben Hansen, T Donner, Jan W. Eriksson, R Jackson, N Krasnopeeva, J Pouzar, E Kazakova, J Gumprecht, Thalia Marie Blicher, E Morawski, S Nieminen, Y Shlesinger, J Parker, Klaus Levin, T Maxwell, Z Shaikh, A Nikkola, E Zhdanova, D Nabriski, T Lysenko, P Norwood, G Vagapova, K Khan, J Eriksson, M Hellgren, Ofri Mosenzon, John Strand, M Hewitt, Naim Shehadeh, B Barker, E Haddad, K Eliasson, Y Pergaeva, T Sathyapalan, M Kunitsyna, Thozhukat Sathyapalan, W Gandy, J Soufer, S Chilka, J Lawhead, P Nicol, M Benson, A Odugbesan, S Aronoff, G Gatipon, R Abramof, L Gonzalez-Orozco, C Desouza, O Mosenzon, I Beshay, H Traylor, B Snyder, Robert S. Lindsay, A Cleland, K Metsärinne, Paweł Bogdański, K Forshaw, M Sergeeva-Kondrachenko, Cyrus Desouza, M Hitz, S Plevin, K Astamirova, N Uhlenius, R Huntley, D Alpenidze, B Delgado, L Zarutskaya, Signe Rosenlund, John A. McKnight, P Levin, E Frolova, S Heller, P E Jakobsen, A Kapoor, R Busch, S Chaidarun, L Connery, S Hietaniemi, Sten Madsbad, M. Shamkhalova, S Lindmark, B Hella, L Belousova, C Mbogua, L Kargina

Publikováno v: Mosenzon, O, Blicher, T M, Rosenlund, S, Eriksson, J W, Heller, S, Hels, O H, Pratley, R, Sathyapalan, T, Desouza, C, PIONEER 5 Investigators, Abramof, R, Alpenidze, D, Aronoff, S, Astamirova, K, Barker, B, Bedel, G, Belousova, L, Benson, M, Beshay, I, Biggs, W, Blaze, K, Bogdanski, P, Busch, R, Chaidarun, S, Chandran, S, Chang, A, Chilka, S, Cleland, A, Connery, L, Cornett, G, Delgado, B, Desouza, C, Donner, T, Eliasson, K, Eriksson, J, Folkerth, S, Forshaw, K, Frandsen, H A, Frolova, E, Gandy, W, Gatipon, G, Golovach, A, Hansen, T K, Hitz, M, Jakobsen, P E, Levin, K, Madsbad, S, Nguyen, H, Parker, J, Reed, J, Rossing, P, Yanovskaya, M, Zarutskaya, L & Zhdanova, E 2019, ' Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5) : a placebo-controlled, randomised, phase 3a trial ', The Lancet Diabetes and Endocrinology, vol. 7, no. 7, pp. 515-527 . https://doi.org/10.1016/S2213-8587(19)30192-5
Mosenzon, O, Blicher, T M, Rosenlund, S, Eriksson, J W, Heller, S, Hels, O H, Pratley, R, Sathyapalan, T, Desouza, C & PIONEER 5 Investigators 2019, ' Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5) : a placebo-controlled, randomised, phase 3a trial ', The Lancet Diabetes & Endocrinology, vol. 7, no. 7, pp. 515-527 . https://doi.org/10.1016/S2213-8587(19)30192-5

Background: Oral semaglutide is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for glycaemic control in patients with type 2 diabetes. Type 2 diabetes is commonly associated with renal impairment, restricting treatment options. We ai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d569511b15de88f728dd8364203edd9
https://curis.ku.dk/ws/files/251035512/Efficacy_and_safety_of_oral_semaglutide_in_patients_with_type_2_diabetes_and_moderate_renal_impairment_PIONEER_5_accepted_version_.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.